153 related articles for article (PubMed ID: 38417963)
1. Investigating the efficacy and safety of olanzapine prophylaxis for opioid-induced nausea and vomiting (JORTC-PAL20): a study protocol for an open-label, single-arm exploratory study.
Satomi E; Kobayashi T; Ishikawa A; Arakawa S; Ishiki H; Amano K; Sakiyama N; Ariyoshi K; Kihara K; Oyamada S; Mizushima A
BMJ Open; 2024 Feb; 14(2):e076575. PubMed ID: 38417963
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial.
Tsukuura H; Miyazaki M; Morita T; Sugishita M; Kato H; Murasaki Y; Gyawali B; Kubo Y; Ando M; Kondo M; Yamada K; Hasegawa Y; Ando Y
Oncologist; 2018 Mar; 23(3):367-374. PubMed ID: 29038236
[TBL] [Abstract][Full Text] [Related]
3. Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracycline/cyclophosphamide regimen (JTOP-B).
Ozeki R; Iihara H; Shimokawa M; Hashimoto H; Abe M; Mukohara T; Bando H; Hayashi T; Kawazoe H; Komoda M; Yanai Takahashi T; Saito M
BMJ Open; 2022 Mar; 12(3):e058755. PubMed ID: 35236735
[TBL] [Abstract][Full Text] [Related]
4. A preliminary study of the effect of naldemedine tosylate on opioid-induced nausea and vomiting.
Sato J; Tanaka R; Ishikawa H; Suzuki T; Shino M
Support Care Cancer; 2020 Mar; 28(3):1083-1088. PubMed ID: 31183560
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy.
Chan A; Low XH; Yap KY
J Manag Care Pharm; 2012 Jun; 18(5):385-94. PubMed ID: 22663171
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic antiemetics for adults receiving intravenous opioids in the acute care setting.
Gottlieb M; Carlson JN; Peksa GD
Cochrane Database Syst Rev; 2022 May; 5(5):CD013860. PubMed ID: 35588093
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.
Sutherland A; Naessens K; Plugge E; Ware L; Head K; Burton MJ; Wee B
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD012555. PubMed ID: 30246876
[TBL] [Abstract][Full Text] [Related]
8. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.
Chow R; Herrstedt J; Aapro M; Chiu L; Lam H; Prsic E; Lock M; DeAngelis C; Navari RM
Support Care Cancer; 2021 Jul; 29(7):3439-3459. PubMed ID: 33442782
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial.
Iihara H; Shimokawa M; Gomyo T; Fujita Y; Yoshida T; Funaguchi N; Minato K; Kaito D; Osawa T; Yamada M; Hirose C; Suzuki A; Ohno Y
BMJ Open; 2019 Jul; 9(7):e028056. PubMed ID: 31278102
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting: a survey about Italian physicians' practice.
Giusti R; Mazzotta M; Filetti M; Daniele G; Tsukuura H; Ficorella C; Porzio G; Marchetti P; Verna L
Support Care Cancer; 2019 Sep; 27(9):3531-3535. PubMed ID: 30684048
[TBL] [Abstract][Full Text] [Related]
11. Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial.
Bajpai J; Kapu V; Rath S; Kumar S; Sekar A; Patil P; Siddiqui A; Anne S; Pawar A; Srinivas S; Bhargava P; Gulia S; Noronha V; Joshi A; Prabhash K; Banavali S; Sarin R; Badwe R; Gupta S
Lancet Oncol; 2024 Feb; 25(2):246-254. PubMed ID: 38224701
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic Use of Antiemetics for Prevention of Opioid-Induced Nausea and Vomiting: A Questionnaire Survey among Japanese Physicians.
Tsukuura H; Ando Y; Gyawali B; Matsumoto M; Sugishita M; Honda K; Urakawa H; Maeda O; Hasegawa Y
J Palliat Med; 2015 Nov; 18(11):977-80. PubMed ID: 26509390
[TBL] [Abstract][Full Text] [Related]
13. Secondary and cumulative meta-analysis of olanzapine for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: do we still need to study its effectiveness?
Chiu L; Chow R; DeAngelis C; Lock M; Simone CB
Ann Palliat Med; 2021 Mar; 10(3):2540-2547. PubMed ID: 33440973
[TBL] [Abstract][Full Text] [Related]
14. Prevention of Opioid-Induced Nausea and Vomiting During Treatment of Moderate to Severe Acute Pain: A Randomized Placebo-Controlled Trial Comparing CL-108 (Hydrocodone 7.5 mg/Acetaminophen 325 mg/Rapid-Release, Low-Dose Promethazine 12.5 mg) with Conventional Hydrocodone 7.5 mg/Acetaminophen 325 mg.
Zuniga JR; Papas AS; Daniels SE; Patrick K; Muse DD; Oreadi D; Giannakopoulos HE; Granquist EJ; Levin LM; Chou JC; Maibach H; Schachtel BP
Pain Med; 2019 Dec; 20(12):2528-2538. PubMed ID: 30657996
[TBL] [Abstract][Full Text] [Related]
15. Economic and clinical burden of opioid-induced nausea and vomiting.
Nicholson BD
Postgrad Med; 2017 Jan; 129(1):111-117. PubMed ID: 27690715
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy.
Slimano F; Netzer F; Borget I; Lemare F; Besse B
Int J Clin Pharm; 2018 Oct; 40(5):1265-1271. PubMed ID: 29744791
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological treatment of cancer pain and opioid induced nausea and vomiting: online survey and comparison with current guidelines.
Gaertner J; Boehlke C; Kreye G; Fusi-Schmidhauser T; Mueller E; Roch C
Support Care Cancer; 2024 Jun; 32(7):436. PubMed ID: 38879720
[TBL] [Abstract][Full Text] [Related]
18. Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B).
Sakai H; Tsurutani J; Ozaki Y; Ishiguro H; Nozawa K; Watanabe K; Maeda S; Yokoe T; Imamura CK; Matsumoto K; Iwasa T; Chiba Y; Takiguchi D; Takano T
BMJ Open; 2023 Apr; 13(4):e070304. PubMed ID: 37012013
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
[TBL] [Abstract][Full Text] [Related]
20. Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis.
Yamamoto S; Iihara H; Uozumi R; Kawazoe H; Tanaka K; Fujita Y; Abe M; Imai H; Karayama M; Hayasaki Y; Hirose C; Suda T; Nakamura K; Suzuki A; Ohno Y; Morishige KI; Inui N
BMC Cancer; 2022 Mar; 22(1):310. PubMed ID: 35321690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
